Posted by
Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings

Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings

Key Points Question  What are the trends across adulterated dietary supplements associated with a warning released by the US Food and Drug Administration from 2007 through 2016? Findings  In this quality improvement study, analysis of the US Food and Drug Administration warnings from 2007 through 2016 showed that unapproved pharmaceutical ingredients were identified in 776 dietary supplements, […]

Posted by
Precision Medicine:The Future is Coming Fast

Precision Medicine:The Future is Coming Fast

Promise of Precision Medicine in Psychiatry Nears Reality BARCELONA, Spain — Innovative approaches and widespread data sharing are essential in psychiatry to improve patient care and deliver on the long-held promise of precision medicine, a leading European expert says. In a plenary lecture delivered here at the 31st European College of Neuropsychopharmacology (ECNP) Congress, Marion […]

Posted by

The APA Brings Genetic Testing Under Fire, Genomind and Genesight Respond

On April 25th 2018 the American Psychiatric Association published the following criticism of genomic testing emphasizing their skepticism towards psychiatrists who are using genetic testing to make informed decisions about diagnosis and treatment. An abstract of their statement reads:       Evidence Does Not Support Commercial Rush Of DNA Tests Designed To Inform Decisions […]

Posted by
FDA Clears 3-Minute Brain Stimulation Protocol for Depression

FDA Clears 3-Minute Brain Stimulation Protocol for Depression

The US Food and Drug Administration (FDA) has approved a newer and faster treatment protocol for the MagVita repetitive transcranial magnetic stimulation (rTMS) therapy system from MagVenture, the company has announced. The FDA first cleared the MagVitaTMS therapy system in 2015 for treatment of adults with drug-resistant major depressive disorder, as reported by Medscape Medical News. Until now, each treatment […]

Posted by
U.S. Food & Drug Administration Letter Regarding Mag Vita TMS Therapy System w/Theta Burst Stimulation

U.S. Food & Drug Administration Letter Regarding Mag Vita TMS Therapy System w/Theta Burst Stimulation

This Letter Shows that TBS is FDA Approved Tonica Elektronik A/S Sanne Jessen Medical Advisor Lucernemarken 15 Farum, 3520 Dk Re: K173620 Trade/Device Name: Mag Vita TMS Therapy System w/Theta Burst Stimulation Regulation Number: 21 CFR 882.5805 Regulation Name: Repetitive Transcranial Magnetic Stimulation System Regulatory Class: Class II Product Code: OBP Dated: July 10, 2018 […]

Posted by
Acetyl-l-carnitine deficiency in patients with major depressive disorder

Acetyl-l-carnitine deficiency in patients with major depressive disorder

Significance Identifying biological targets in major depressive disorder (MDD) is a critical step for development of effective mechanism-based medications. The epigenetic agent acetyl-L-carnitine (LAC) has rapid and enduring antidepressant-like effects in LAC-deficient rodents. Here, we found that LAC levels were decreased in patients with MDD versus age- and sex-matched healthy controls in two independent study […]

Posted by
Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States

Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States

June 12, 2018 Key Points Question  How frequently do US adults use prescription medications with depression as a potential adverse effect and is use of these medications associated with concurrent depression? Findings  In this cross-sectional US population-based survey study conducted between 2005 and 2014, the estimated overall prevalence of US adults using medications with depression as a potential adverse […]

Posted by
Magnetic Brain Stimulation Flops in VA Trial: Both sham and active rTMS produce high remission rates; unclear why

Magnetic Brain Stimulation Flops in VA Trial: Both sham and active rTMS produce high remission rates; unclear why

by Elizabeth Hlavinka, MedPage Today InternJune 27, 2018 About 40% of patients with treatment-resistant major depression achieved remission in a randomized trial of repetitive transcranial magnetic stimulation (rTMS) — but the rate was virtually the same with sham treatment versus active stimulation, researchers said. Among 81 patients in Veterans Affairs medical centers assigned to active rTMS, 33 […]